Edithistory:Xeruborbactam
From EverybodyWiki Bios & Wiki
| oldid | date/time | username | edit summary |
|---|---|---|---|
| 1317671664 | 2025-10-19T10:25:57Z | KylieTastic | draft |
| 1315192249 | 2025-10-05T09:41:18Z | Boghog | /* Clinical development */ added table of clinical trials |
| 1315191653 | 2025-10-05T09:35:27Z | Boghog | /* Spectrum of activity */ wikify |
| 1315191557 | 2025-10-05T09:34:30Z | Boghog | /* Mechanism of action */ wikify |
| 1315191167 | 2025-10-05T09:30:09Z | Citation bot | Add: doi-access, article-number. Removed parameters. Some additions/deletions were parameter name changes. | [[:en:WP:UCB|Use this bot]]. [[:en:WP:DBUG|Report bugs]]. | Suggested by Headbomb | #UCB_toolbar |
| 1315191102 | 2025-10-05T09:29:36Z | Boghog | copyedit to reduce the hype; added review article citation |
| 1315190295 | 2025-10-05T09:22:05Z | Boghog | + graphics; added chemical categories |
| 1315188813 | 2025-10-05T09:05:25Z | Boghog | added missing data to drug box |
| 1315185809 | 2025-10-05T08:30:54Z | Boghog | consistent citation formatting; correct errors in drug box |
| 1315080660 | 2025-10-04T19:27:37Z | Mousumi701 | |
| 1315079145 | 2025-10-04T19:18:10Z | ChildrenWillListen | Added {{[[Template:COI|COI]]}} tag |
| 1315077003 | 2025-10-04T19:05:56Z | Mousumi701 | |
| 1315069397 | 2025-10-04T18:20:11Z | ChildrenWillListen | Added {{[[Template:COI|COI]]}} tag |
| 1315069350 | 2025-10-04T18:19:53Z | ChildrenWillListen | [[WP:AFC|AFC]] draft |
| 1315069346 | 2025-10-04T18:19:52Z | ChildrenWillListen | ChildrenWillListen moved page [[Xeruborbactam]] to [[Draft:Xeruborbactam]]: [[WP:DRAFTIFY|Not ready]] for mainspace, incubate in draftspace. See author's page creation log, etc. Reason/s: more sources needed, possible COI |
| 1315060454 | 2025-10-04T17:14:51Z | Mousumi701 | |
| 1315057151 | 2025-10-04T16:53:02Z | Mousumi701 | |
| 1315057095 | 2025-10-04T16:52:37Z | Mousumi701 | |
| 1315056904 | 2025-10-04T16:51:28Z | Mousumi701 | |
| 1315056683 | 2025-10-04T16:50:01Z | Mousumi701 | [[WP:AES|←]]Created page with '** [[Xeruborbactam]], the first nanomolar β-lactamase inhibitor in clinical development, has very broad-spectrum efficacy against all Ambler classes (A–D), including OXA carbapenemases and metallo-enzymes. It is a boronic acid-based transition-state analogue that strongly inhibits carbapenemases with a Ki(app) of 4 nM, which is more effective than current inhibitors. Structural investigations showed that the cyclopropyl group covalently binds to Ser70 an...' |
